网络荟萃分析比较VenaSeal与其他浅静脉疗法治疗慢性静脉功能不全
本研究通过网络荟萃分析比较VenaSeal与其他浅静脉干预(EVLA、RFA、机械化学消融、硬化疗法、手术)治疗慢性静脉功能不全的效果。纳入20项RCT共4570例患者,结果显示VenaSeal在6个月解剖成功概率排名第一(P=.980),术后疼痛减轻排名第一(P=.690),不良事件发生率最低(P=.650)。
要点
- VenaSeal在6个月解剖成功概率排名第一(P=.980)。
- VenaSeal术后疼痛减轻排名第一(P=.690),不良事件发生率最低(P=.650)。
- VenaSeal在VCSS和AVVQ排名第三,EQ-5D排名第五,但证据不足。
核心结论
- VenaSeal在6个月解剖成功方面概率排名第一(P=.980),且不良事件(伤口和腹股沟感染、肺栓塞)发生概率最低(P=.650)。
研究设计与样本
- 系统检索1996年1月至2018年9月的随机对照试验(RCT),最终纳入20项RCT共4570例患者,采用贝叶斯固定或随机效应模型进行网络荟萃分析。
主要发现
- 解剖成功概率排名:VenaSeal第一(P=.980),RFA第二(P=.365),EVLA第三(P=.397),手术第四(P=.290),机械化学消融第五(P=.695),硬化疗法第六(P=.982)。
- VenaSeal在VCSS排名第三(P=.332),EQ-5D排名第五(P=.420),AVVQ排名第三(P=.300),但95%可信区间提示证据不足。
- VenaSeal术后疼痛评分较基线下降排名第一(P=.690),不良事件发生概率最低(P=.650)。
- 不良事件发生比值比:硬化疗法为VenaSeal的3.3倍,EVLA为2.7倍,手术为1.6倍,RFA为1.1倍。
临床怎么用
- 对于慢性静脉功能不全患者,VenaSeal在6个月解剖成功和减少不良事件方面可能具有优势,但需结合个体情况和成本效益综合决策。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Several randomized controlled trials (RCTs) have compared different interventions for chronic venous insufficiency (CVI) management, but mixed comparison of these interventions is lacking. The aim of this network meta-analysis was to compare VenaSeal closure system (Medtronic, Minneapolis, Minn) with endovenous laser ablation (EVLA), radiofrequency ablation (RFA), mechanochemical ablation, sclerotherapy, and surgery for management of CVI to achieve anatomic success (complete closure of treated vein within 6 months after intervention) as the primary outcome and health-related quality of life (HRQoL; EuroQol-5 Dimension, Aberdeen Varicose Vein Questionnaire), Venous Clinical Severity Score (VCSS), pain scores, and adverse events as secondary outcomes. METHODS: A systematic review of journal databases was undertaken, and RCTs between January 1996 and September 2018 comparing different treatment options were included. Risk of bias and quality of publications were assessed using the Cochrane bias tool; Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used for study selection and reporting. Twenty RCTs comprising 4570 patients were analyzed. Data for anatomic success, VCSS, HRQoL, pain score, and adverse events were extracted and analyzed using mixed treatment comparison in a network meta-analysis. A Bayesian fixed or random effects model was selected for analysis. Rank probability graphs were generated for various treatments and corresponding ranks obtained to estimate their probability of being best. Relative treatment effects were calculated in terms of log odds ratios for anatomic success and adverse events. Mean difference was calculated for VCSS, HRQoL, and pain score. RESULTS: For the primary outcome measure (anatomic success), VenaSeal system had the highest probability of being ranked first (P = .980); RFA was ranked second (P = .365), EVLA third (P = .397), surgery fourth (P = .290), mechanochemical ablation fifth (P = .695), and sclerotherapy sixth (P = .982). For secondary outcome measures, VenaSeal system ranked third for VCSS (P = .332), fifth for EuroQol-5 Dimension (P = .420), and third for Aberdeen Varicose Vein Questionnaire (P = .300). Although, VenaSeal system was slightly inferior to some of the other interventions for HRQoL, the 95% credible interval of log odds ratio indicated insufficient evidence for any concrete conclusion to be drawn. VenaSeal system ranked first in reduction of postoperative pain score from baseline (P = .690) and was lowest in occurrence of adverse events (P = .650). Odds of occurrence of adverse events was 3.3 times in the sclerotherapy arm, 2.7 times in the EVLA arm, 1.6 times with surgery, and 1.1 times with RFA vs VenaSeal system arm. CONCLUSIONS: VenaSeal system is a promising therapeutic option for anatomic success at 6 months, with fewer occurrences of adverse events (wound and groin infection, pulmonary embolism) in CVI patients compared with other interventions in this study. Additional economic analysis including cost-effectiveness analysis would provide interesting perspectives on real-world insights to patients, payers, and providers.
引用
- Kolluri R, Chung J, Kim S, et al. Network meta-analysis to compare VenaSeal with other superficial venous therapies for chronic venous insufficiency. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 32063522. doi:10.1016/j.jvsv.2019.12.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。